Actively Recruiting
Observing Treatment Patterns and Outcomes in Adult Men with Metastatic Castration-Resistant Prostate Cancer Using the PRECISION Data Platform
Led by Novartis Pharmaceuticals · Updated on 2026-07-16
17111
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying men diagnosed with metastatic castration-resistant prostate cancer mCRPC in the United States to understand their treatment patterns, clinical outcomes, and patient characteristics in everyday medical practice. This observational study uses data from the PRECISION data platform to gather real-world information on this condition. Participants are adult males recently diagnosed with mCRPC. The study observes their treatments over time, including prior therapies and multiple lines of therapy, without administering experimental interventions. It tracks therapy types, switches between therapies, and timing of treatment initiation and changes over a period of up to approximately five years. During the study, researchers will collect and analyze data on patient characteristics, treatments received, progression-free survival, and overall survival. The primary outcomes focus on therapy use and timing, while secondary outcomes include survival measures. Participation involves data observation only, with no direct treatment assigned, and will continue for up to five years from diagnosis.
CONDITIONS
Brief Title
A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
